Video | 08 February 2019 TB survivors challenge J&J's patent on TB drug in India TUBERCULOSIS India Phumeza and Nandita suffered permanent hearing loss because of toxic drugs used to treat their drug-resistant TB. Now they’re working to ensure that this doesn’t happen to anyone else. Read, watch, share Filter by - Any -ExplainerFeature storyIssue briefLetterNewsletterPhoto storyPress releaseReportResearch articleSpeechStatementVideo Press release Press release | 17 July 2024 Tuberculosis MSF welcomes Indian Patent Office’s rejection of J&J’s application for paediatric formulation of lifesaving TB drug 4 min Press release | 05 July 2024 Intellectual property and trade Tuberculosis South Africa MSF and Health Justice Initiative welcome J&J’s withdrawal of patents on lifesaving TB drug in South Africa Photo credit: Andrea Bussotti Press release Press release | 07 November 2023 Tuberculosis MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease 4 min Photo credit: Negin Allamehzadeh Press release Press release | 30 September 2023 Tuberculosis MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries 3 min Letter | 21 September 2023 Intellectual property and trade Republic of Moldova Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis Letter | 21 September 2023 Tuberculosis Ukraine Ukraine: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis Letter | 21 September 2023 Tuberculosis Azerbaijan Azerbaijan: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis Letter | 21 September 2023 Intellectual property and trade Ukraine Ukraine: Open Letter: Urgent action by Johnson & Johnson needed to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis Load More
Press release Press release | 17 July 2024 Tuberculosis MSF welcomes Indian Patent Office’s rejection of J&J’s application for paediatric formulation of lifesaving TB drug 4 min
Press release | 05 July 2024 Intellectual property and trade Tuberculosis South Africa MSF and Health Justice Initiative welcome J&J’s withdrawal of patents on lifesaving TB drug in South Africa
Photo credit: Andrea Bussotti Press release Press release | 07 November 2023 Tuberculosis MSF responds to WHO’s annual global TB report: implores governments to use recent TB wins to beat back deadly infectious disease 4 min
Photo credit: Negin Allamehzadeh Press release Press release | 30 September 2023 Tuberculosis MSF responds to groundbreaking news that Johnson & Johnson will not enforce patents on key TB drug bedaquiline in low- and middle-income countries 3 min
Letter | 21 September 2023 Intellectual property and trade Republic of Moldova Moldova: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis
Letter | 21 September 2023 Tuberculosis Ukraine Ukraine: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis
Letter | 21 September 2023 Tuberculosis Azerbaijan Azerbaijan: Open Letter: CSOs request urgent action by Johnson & Johnson to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis
Letter | 21 September 2023 Intellectual property and trade Ukraine Ukraine: Open Letter: Urgent action by Johnson & Johnson needed to improve equitable access to bedaquiline-based regimens in all countries with a high burden of tuberculosis